Aldeyra Therapeutics Inc

NASDAQ:ALDX  
3.67
+0.08 (+2.23%)
Products, Regulatory

Aldeyra Therapeutics Achieves Primary Endpoint In Phase 3 Trial In Dry Eye Disease

Published: 06/08/2022 11:40 GMT
Aldeyra Therapeutics Inc (ALDX) - Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Tranquility‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease.
Aldeyra Therapeutics Inc - Pending Pre-nda Meeting With U.S. Food and Drug Administration (fda), Clinical Efficacy Trials of Reproxalap Believed to Be Complete.
Aldeyra Therapeutics Inc - Enrollment of Crossover Dry Eye Disease Trial is Substantially Complete, and Results Are Expected in Q3 of 2022.
Aldeyra Therapeutics Inc - Tranquility-2 Results May Allow for Most Comprehensive Dry Eye Disease NDA Submission to Date.
Aldeyra Therapeutics - Reproxalap Statistically Superior to Vehicle for Both Prespecified Primary Endpoints.